hydrocodone; dihydrocodeinone (Zohydro ER, Hysingla ER)

From Aaushi
Jump to navigation Jump to search

Introduction

Prior to 2014, DEA-controlled substance: class 3.

All hydrocodone combinations to became class 2 Oct 6, 2014.[4][5][7]

Indications

Dosage

  • 5 mg PO every 4-6 hours

Extended-release:

  • Zohydro ER: 50 mg
  • Hysingla ER (abuse-deterrent): 20,30,40,60,80,100,120 mg[6]

Pharmacokinetics

elimination via liver

1/2life = 4 hours

Adverse effects

Drug interactions

  • any pharmaceutical agent that inhibits cyt P450 2D6 may increase levels of hydrocodone
  • see opiate

Laboratory

Mechanism of action

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 - not on National VA formulary
  3. FDA New Release: Oct. 25, 2013 FDA approves extended-release, single-entity hydrocodone product. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm372287.htm
  4. 4.0 4.1 Food and Drug Administration (FDA). Oct 24, 2013 Statement on Proposed Hydrocodone Reclassification from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research. http://www.fda.gov/drugs/drugsafety/ucm372089.htm
  5. 5.0 5.1 Prescriber's Letter 21(9): 2014 PDF: DEA Update on Rescheduling of Hydrocodone Combination Products (August 21, 2014) CHART: Equianalgesic Dosing of Opioids for Pain Management LETTER: A Note from Your Pharmacist: Hydrocodone Combinations are Moving from Schedule III to Schedule II PATIENT EDUCATION HANDOUT: Changes for Hydrocodone Combinations Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=300943&pb=PRL (subscription needed) http://www.prescribersletter.com
  6. 6.0 6.1 FDA News Release. November 20, 2014 FDA approves extended-release, single-entity hydrocodone product with abuse-deterrent properties http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm423977.htm
  7. 7.0 7.1 Habbouche J, Lee J, Steiger R et al Association of Hydrocodone Schedule Change With Opioid Prescriptions Following Surgery. JAMA Surg. Published online August 22, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30140896 https://jamanetwork.com/journals/jamasurgery/article-abstract/2696622
  8. Barakat NH, Atayee RS, Best BM, Ma JD Urinary Hydrocodone and Metabolite Distributions in Pain Patients Journal of Analytical Toxicology. 2014 38(7):404-409 September PMID: https://www.ncbi.nlm.nih.gov/pubmed/2483689 https://academic.oup.com/jat/article/38/7/404/2797996

Database